Please note that the details of this Challenge are no longer open. This challenge is closed and is no longer accepting new submissions. You can:

GSK & Save the Children:  $1M Healthcare Innovation Award to Fight Child Mortality

TAGS:Public Good Life Sciences Global Health Chemistry Computer Science/Information Technology Food/Agriculture Engineering/Design Developing Countries Requests for Partners and Suppliers
AWARD:  varies
POSTED: 6/24/13


This Challenge is closed and is no longer accepting new submissions.


To access the fourth annual Healthcare Innovation Award, click here



GlaxoSmithKline and Save the Children have launched a fund totalling $1,000,000 to reward organisations practicing innovative approaches for reducing under-5 child mortality. The organisation judged to combat child mortality in the most innovative and effective way will be eligible for an award of up to $250,000. 

Eligible innovative organisations can come from the non-profit, private or public sector, if both the organisation and the innovation are from the developing world. Nominations can be submitted by the organisation themselves, or by a third-party organisation or individual, through a brief questionnaire found within the detailed guidelines.

Source: InnoCentive
Challenge ID: 9933399
Team Project Rooms are available on this Challenge Team Share Challenge Share
Challenge Overview

GlaxoSmithKline (GSK) and Save the Children are working in partnership to fight child mortality in developing countries. An award fund of $1,000,000 has been made available by GSK for organisations practicing innovative approaches to reduce mortality rates in children under-5 years. 

This is an electronic Request-for-Partners (eRFP) Challenge, but you do not need to represent the innovative organisation in order to make a nomination! Nominations must be submitted using the provided template. GSK and Save the Children will jointly evaluate nominated organisations and select organisations for a monetary award.  During this evaluation, GSK and/or Save the Children may contact selected organisations directly to carry out brief due diligence and make further arrangements as necessary. The monetary value of awards made will be based on the Judging Panel’s assessment of submissions against award criteria and will vary between submissions. 

Award winners selected by GSK and Save the Children will be publically announced and their innovative practices promoted within 3 months of the end of the nomination period.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements. What is an eRFP Challenge?

eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.

After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.

This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.

Share This Challenge
InnoCentive Trust Partners